| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
CysLT1 (cysteinyl leukotriene receptor 1)
|
|---|---|
| ln Vitro |
Montelukast (5 μM; 1 h) prevents cell damage caused by APAP (acetaminophen) (HY-66005)[1].
Montelukast (0.01-10 μM; 30 min) attenuates the plasmin-plasminogen system activation and reduces the 5-oxo-ETE-induced cell migration[3]. Montelukast (10 μM; 18 h) modifies MMP-9 activation[3]. |
| ln Vivo |
Montelukast (3 mg/kg; oral gavage) shields mice's livers from APAP-induced hepatotoxicity[1].
Montelukast (1 mg/kg; miniosmotic pump administration) inhibits the effects of cysteinyl leukotrienes (LT) C4, D4, and E4, which are mediated by the CysLT1 receptor, and lessens the alterations in airway remodeling seen in mice given OVA[2]. Montelukast (1 mg/kg; miniosmotic pump administration) lowers the elevated levels of IL-4 and IL-13 in the BAL fluid of mice treated with OVA[2]. |
| Enzyme Assay |
Montelukast and MK-0591 decreased eosinophil migration promoted by 5-oxo-ETE, whereas LTD(4) failed to induce eosinophil migration. However, LTD(4) significantly boosted the migration rate obtained with a suboptimal concentration of 5-oxo-ETE and partially reversed the inhibition obtained with MK-0591. Montelukast significantly reduced the maximal rate of activation of plasminogen into plasmin by eosinophils obtained with 5-oxo-ETE. 5-Oxo-ETE increased the number of eosinophils expressing urokinase plasminogen activator receptor and stimulated secretion of MMP-9. Montelukast, but neither MK-0591 nor LTD(4), reduced the expression of urokinase plasminogen activator receptor and the secretion of MMP-9 and increased total cellular activity of urokinase plasminogen activator and the expression of plasminogen activator inhibitor 2 mRNA [3].
|
| Cell Assay |
Cell Line: Eosinophils
Concentration: 0.01-10 μM
Incubation Time: 30 min
Result: Diminished the 5-oxo-ETE–induced cell migration.
|
| Animal Protocol |
C57BL/6J mice (8-week-old; 22-25 g) are induced acute hepatic injury
3 mg/kg Oral gavage 1 h after saline or APAP administration |
| ADME/Pharmacokinetics |
Absorption, Distribution, and Excretion
Absorption Montelukast is observed to be rapidly absorbed after oral administration. The oral bioavailability of this drug is 64%. Furthermore, it appears that normal morning meals or high-fat snacks in the evening do not affect the absorption of montelukast. Excretion Route Montelukast and its metabolites are reported to be almost entirely excreted via bile and feces. Volume of Distribution The steady-state volume of distribution of montelukast is on average 8 to 11 liters. Clearance The average plasma clearance of montelukast observed in healthy adults is 45 mL/min. Montelukast is rapidly absorbed from the gastrointestinal tract. After oral administration of a single 10 mg film-coated tablet (adult), 5 mg chewable tablet (adult), or 4 mg chewable tablet (child) on an empty stomach, peak plasma concentrations are reached in 3–4 hours, 2–2.5 hours, or 2 hours, respectively. (For children aged 2–5 years) tablets. …When taking the 4 mg oral granules in the morning, consuming a high-fat meal had no effect on the AUC of montelukast; however, the time to peak plasma concentration was prolonged from 2.3 hours to 6.4 hours, and the peak plasma concentration decreased by 35%. Montelukast is rapidly absorbed. The mean oral bioavailability of the 10 mg tablets is 64%. A standard morning meal does not affect bioavailability. For the 5 mg chewable tablets: the mean oral bioavailability on an empty stomach is 73%, while it is 63% when taken with a standard meal in the morning. View MoreIn fasting young adults, after daily oral administration of 10 mg montelukast for 7 consecutive days, the mean peak plasma concentration on day 1 was 541 ng/mL, and the mean peak plasma concentration on day 7 was 602.8 ng/mL. The trough concentrations remained relatively stable from day 3 to day 7, ranging from 18 to 24 ng/mL. In this study, the area under the steady-state plasma concentration-time curve (AUC) was approximately 14-15% higher than that after a single dose, and this was achieved within 2 days. For more complete data on absorption, distribution, and excretion of montelukast (15 items in total), please visit the HSDB record page. Metabolism/Metabolites Montelukast has been identified as actively metabolized, typically by cytochrome P450 3A4, 2C8, and 2C9 isoenzymes. In particular, the CYP2C8 enzyme appears to play a significant role in drug metabolism. However, at therapeutic doses, plasma concentrations of montelukast metabolites are undetectable in both adult and pediatric patients at steady state. Biotransformation occurs primarily in the liver, involving cytochrome P450 3A4 and 2C9. The metabolic pathways of montelukast are not fully understood, but the drug is extensively metabolized in the gastrointestinal tract and/or liver and excreted via bile. Multiple metabolic pathways have been identified, including acyl glucuronidation and oxidation catalyzed by various cytochrome P-450 (CYP) isoenzymes. In vitro studies have shown that the microsomal P-450 isoenzyme CYP3A4 is the major enzyme in the formation of the 21-hydroxy metabolite (M5) and the sulfoxide metabolite (M2), while CYP2C9 is the major isoenzyme in the formation of the 36-hydroxy metabolite (M6). Other identified metabolites include acylglucuronide (M1) and a 25-hydroxy (phenolic, M3) analog. Following oral administration of 54.8 mg of radiolabeled montelukast, drug metabolites account for less than 2% of circulating radioactivity. In radiolabeling studies, montelukast metabolites identified in plasma include 21-hydroxy (benzyl acid diastereomers, M5a and M5b) metabolites and 36-hydroxy (methanol diastereomers, M6a and M6b) metabolites. Following oral administration of a therapeutic dose of montelukast, steady-state plasma metabolite concentrations in both adults and children were below the limit of detection. The known metabolites of montelukast include 21-hydroxymontelukast, 21(S)-hydroxymontelukast, montelukast 1,2-diol, and montelukast sulfoxide. Biological Half-Life Studies have shown that the mean plasma half-life of montelukast in healthy young adults is 2.7 to 5.5 hours. The mean plasma elimination half-life of montelukast in adults aged 19–48 years is 2.7–5.5 hours, with a mean plasma clearance of 45 mL/min. The plasma elimination half-life in children aged 6–14 years is 3.4–4.2 hours. Limited data suggest that the plasma elimination half-life of montelukast is slightly prolonged in older adults and patients with mild to moderate hepatic impairment, but no dose adjustment is required. The plasma elimination half-lives in older adults aged 65–73 years and patients with mild to moderate hepatic impairment have been reported to be 6.6 hours and 7.4 hours, respectively. |
| Toxicity/Toxicokinetics |
Hepatotoxicity
In clinical trials, mild elevations in serum transaminase (ALT) levels were observed in 1% to 2% of patients taking montelukast long-term, but a similar incidence was reported in the matched placebo group. ALT abnormalities are usually mild, asymptomatic, and self-limiting. Clinically significant liver injury caused by montelukast is rare, but a dozen cases have been reported in the literature. In these cases, the latency period of liver injury varies greatly, ranging from days to years. Patients present with anorexia, nausea, right upper quadrant pain, dark urine, and jaundice. The pattern of enzyme elevation is usually mixed, but hepatocellular or cholestatic patterns have also been reported. Allergic reactions and autoantibody formation are rare. Eosinophilia is common, but this may be due to an underlying allergic disease rather than liver injury. After discontinuation of the drug, the injury usually resolves within 1 to 4 months. Probability score: B (Rare but likely a cause of clinically significant liver injury). Effects during pregnancy and lactation ◉ Overview of medication use during lactation Montallukast is present in extremely low amounts in breast milk. Montelukast is approved for use in infants 6 months and older and has been used in newborns at doses far higher than those found in breast milk. It is expected that the dose ingested by breastfed infants will not cause any adverse effects. International guidelines consider leukotriene receptor antagonists to be safe for use during lactation. ◉ Effects on breastfed infants As of the revision date, no relevant published information was found. ◉ Effects on lactation and breast milk As of the revision date, no relevant published information was found. View More◈ What is Montelukast? Drug Interactions Concomitant use of phenobarbital results in a significant decrease in the area under the curve (AUC) of montelukast (approximately 40%) and induces hepatic metabolism…Thomson/Micromedex. Medical Information for Healthcare Professionals, Vol. 1, Greenwood Village, Colorado, 2007, p. 2030. This study aimed to evaluate whether clinically used dose levels of montelukast interfered with the anticoagulant effect of warfarin. In a two-cycle, double-blind, randomized crossover study, 12 healthy male subjects received a single oral dose of 30 mg warfarin on day 7 of a 12-day montelukast treatment regimen, or montelukast 10 mg orally daily, or placebo. Montelukast had no significant effect on the area under the plasma concentration-time curve (AUC) or peak plasma concentration of either R-warfarin or S-warfarin. However, in the presence of montelukast, a slight but statistically significant reduction was observed in the time to peak concentration of both warfarin enantiomers and the elimination half-life of the less potent R-warfarin. These changes were considered clinically insignificant. Montelukast had no significant effect on the anticoagulant effect of warfarin, as assessed by the international normalized ratio of prothrombin time (INR) (AUC 0-144 and maximum INR). The results of this study indicate that clinically significant drug interactions are unlikely to occur in patients requiring concurrent use of these two medications. Protein Binding Montelukast has been determined to bind to plasma proteins at a rate exceeding 99%. |
| References | |
| Additional Infomation |
Montelukast belongs to the quinoline class of compounds, monocarboxylic acids, and aliphatic sulfides. It is a leukotriene antagonist with pharmacological effects of anti-asthma and antiarrhythmia. It is the conjugate acid of montelukast (1-). Montelukast was first approved for clinical use by the US FDA in 1998, and Merck's brand name is Singulair. This drug belongs to the class of leukotriene receptor antagonists (LTRAs). Although LTRAs such as montelukast have shown efficacy, they are usually used as adjunctive or complementary medications in combination with inhaled corticosteroids or other drugs in the asthma ladder. Nevertheless, in 2008-2009, the US Food and Drug Administration (FDA) led an investigation into the potential neuropsychiatric side effects of montelukast, such as agitation, hallucinations, and suicidal behavior. Although these side effects are now listed in the official prescribing information for montelukast, the drug is still widely used globally, with millions of prescriptions issued annually, and generic and brand-name versions are currently available. Montelukast is a leukotriene receptor antagonist. Its mechanism of action is as a leukotriene receptor antagonist. Montelukast is an oral leukotriene receptor antagonist widely used for the prevention and chronic treatment of asthma, but it has been reported to be associated with rare cases of clinical liver injury. Montelukast is a selective cysteyl leukotriene receptor antagonist with anti-inflammatory and bronchodilatory effects. After administration, montelukast selectively and competitively blocks the cysteyl leukotriene 1 (CysLT1) receptor, thereby preventing the binding of the inflammatory mediator leukotriene D4 (LTD4). Inhibition of LTD4 activity suppresses leukotriene-mediated inflammatory events, including eosinophil and neutrophil migration, leukocyte adhesion to vascular endothelium, monocyte and neutrophil aggregation, increased airway edema, increased capillary permeability, and bronchoconstriction. CysLT1 receptors are present in a variety of tissues, including the spleen, lungs, placenta, small intestine, and nasal mucosa, and in a variety of cell types, including monocytes/macrophages, mast cells, eosinophils, CD34-positive hematopoietic progenitor cells, neutrophils, and endothelial cells.
View MoreDrug Indications Therapeutic Uses Antiasthmatic; Leukotriene Antagonist Montalukast is indicated for the prevention and chronic treatment of asthma in adults and children 12 months and older. /US Product Label Includes/ Drug Warnings Headache is the most common adverse reaction to montelukast, occurring in 18-19% of children aged 6 years and older, adolescents, and adults. Headache has been reported in at least 2% of asthmatic children aged 2-8 years receiving montelukast; and in at least 1% (and at a higher rate than in the placebo group) of asthmatic adults and adolescents aged 15 years and older receiving montelukast. In adults and adolescents aged 15 years and older with perennial allergic rhinitis treated with montelukast, sinus headache occurred in at least 1% of patients, with a higher incidence than in the placebo group. In clinical studies, approximately 1.8–1.9% of patients aged 15 years and older experienced dizziness or weakness/fatigue after treatment with this drug. Additionally, reports indicate that this drug may cause abnormal dreams, hallucinations, agitation (including aggressive behavior), paresthesia/hypopnea, somnolence, insomnia, irritability, or restlessness. Reports of seizures are very rare. In patients aged 15 years and older treated with montelukast, abdominal pain occurred in 2.9% of cases. In this age group, dyspepsia, infectious gastroenteritis, and toothache were reported in 2.1%, 1.5%, and 1.7% of cases, respectively. In children aged 6–14 years treated with montelukast, at least 2% reported diarrhea or nausea. In children aged 2–5 years with asthma, at least 2% reported abdominal pain, diarrhea, and gastroenteritis, with an incidence higher than in the placebo group. In children aged 6–8 years with asthma, at least 2% reported gastroenteritis, with an incidence higher than in the placebo group. Post-marketing surveillance data showed that montelukast treatment may also cause adverse reactions such as nausea, vomiting, dyspepsia, pancreatitis (rare), and diarrhea. Pharmacodynamics Montelukast is a leukotriene receptor antagonist with significant affinity and selectivity for cysteyl leukotriene receptor type 1, superior to many other important airway receptors, such as prostaglandin receptors, cholinergic receptors, or β-adrenergic receptors. Therefore, even at doses as low as 5 mg, it can significantly block LTD4 leukotriene-mediated bronchoconstriction. Furthermore, a placebo-controlled crossover study (n=12) showed that montelukast inhibited early and late bronchoconstriction induced by antigen stimulation by 75% and 57%, respectively. Of particular note is that literature documents indicate montelukast can induce bronchodilation within 2 hours of oral administration. This effect can also be additive with the bronchodilation effect produced by co-administration of β-receptor agonists. However, clinical studies in adults aged 15 years and older have shown that daily administration of more than 10 mg of montelukast does not provide additional clinical benefit. Furthermore, in clinical trials involving asthmatic patients aged 6 to 14 years, it was found that during double-blind treatment, montelukast reduced the median peripheral blood eosinophil count by approximately 13% to 15% compared to placebo. Simultaneously, in patients aged 15 years and older with seasonal allergic rhinitis, montelukast also reduced the median peripheral blood eosinophil count by 13% compared to placebo. Mechanism of Action: Cysteinyl leukotrienes (CysLTs), such as LTC4, LTD4, and LTE4, are eicosate compounds released by various cells, including mast cells and eosinophils. When these CysLTs bind to their corresponding CysLT receptors (such as CysLT type 1 receptors) located on respiratory smooth muscle cells, airway macrophages, and various pro-inflammatory cells (such as eosinophils and certain specific myeloid stem cells), they stimulate activity that promotes the pathophysiological processes of asthma and allergic rhinitis. Specifically, CysLT-mediated effects such as airway bronchoconstriction, mucus secretion obstruction, increased vascular permeability, and eosinophil recruitment all contribute to the development of asthma. On the other hand, in allergic rhinitis, the nasal mucosa releases CysLTs upon exposure to allergens during the early and late reactions, and these releases participate in inducing symptoms of allergic rhinitis, such as nasal congestion and airway obstruction. Montelukast, a leukotriene receptor antagonist, binds with high affinity and selectivity to CysLT type 1 receptors, thereby inhibiting any physiological effects of CysLTs (such as LTC4, LTD4, and LTE4) on the receptors, which may promote the development of asthma or allergic rhinitis. Montelukast inhibits bronchoconstriction induced by antigen stimulation. Montelukast is a selective leukotriene receptor antagonist that antagonizes the cysteyl leukotriene (CysLT1) receptor. Cysteine leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism, released by various cells, including mast cells and eosinophils. They bind to cysteyl leukotriene receptors (CysLT) present in the human respiratory tract. The binding of cysteyl leukotrienes to leukotriene receptors is closely related to the pathophysiological processes of asthma, including airway edema, smooth muscle contraction, and altered cellular activity associated with inflammatory processes, all of which contribute to the signs and symptoms of asthma. Montelukast binds to the CysLT1 receptor with high affinity and selectivity, preferentially binding to CysLT1 rather than other pharmacologically significant airway receptors, such as prostaglandin receptors, cholinergic receptors, or β-adrenergic receptors. Montelukast inhibits the physiological effects of LTD4 on CysLT1 receptors without any agonist activity. Thomson/Micromedex, Pharmaceutical Information for Healthcare Professionals, Vol. 1, Greenwood Village, Colorado, 2007, p. 2029. Due to the role of leukotrienes in the pathogenesis of asthma, modulating leukotriene activity can be used to alleviate airway symptoms, reduce bronchial smooth muscle tone, and improve asthma control. Inhibition of leukotriene-mediated effects can be achieved by blocking 5-lipoxygenase activity and inhibiting leukotriene production (e.g., zileutone) or by antagonizing leukotriene activity at specific airway receptor sites (e.g., montelukast, zafirlukast). Montelukast's antagonistic activity is selective, competitive, and reversible. Montelukast competitively inhibits the action of LTD4 on the CysLT receptor subset (CysLT1) in airway smooth muscle. In vitro studies have shown that montelukast has a similar affinity for the CysLT1 receptor as LTD4. In vitro studies showed that montelukast antagonized LTD4-induced contraction of isolated animal smooth muscle, but not LTC4-induced contraction. Animal experiments demonstrated that montelukast antagonized respiratory smooth muscle contraction induced by LTD4 or the antigen. |
| Molecular Formula |
C47H59CLN2O3S
|
|---|---|
| Molecular Weight |
767.50096
|
| Exact Mass |
766.393
|
| CAS # |
577953-88-9
|
| Related CAS # |
Montelukast sodium; 151767-02-1; Montelukast; 158966-92-8
|
| PubChem CID |
16202490
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
65-67°C (lit.)
|
| LogP |
12.58
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
54
|
| Complexity |
1010
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O.C1CCC(CC1)NC2CCCCC2
|
| InChi Key |
ZLOLVGQQYDQBMP-HKHDRNBDSA-N
|
| InChi Code |
InChI=1S/C35H36ClNO3S.C12H23N/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;1-3-7-11(8-4-1)13-12-9-5-2-6-10-12/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);11-13H,1-10H2/b15-10+;/t32-;/m1./s1
|
| Chemical Name |
2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid;N-cyclohexylcyclohexanamine
|
| Synonyms |
Montelukast dicyclohexylamine; Montelukast Dicyclohexylamine Salt; 577953-88-9; Montelukast (dicyclohexylamine); Montelukast dicyclohexylamine; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid;N-cyclohexylcyclohexanamine; Montelukast DCHA; Montelukastdicyclohexylamine; SCHEMBL919528; MK0476 dicyclohexylamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3029 mL | 6.5147 mL | 13.0293 mL | |
| 5 mM | 0.2606 mL | 1.3029 mL | 2.6059 mL | |
| 10 mM | 0.1303 mL | 0.6515 mL | 1.3029 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00934713 | COMPLETED | Drug: montelukast | Lung Disease, Obstructive Signs and Symptoms, Respiratory |
University of Helsinki | 2004-09 | Phase 4 |
| NCT00453765 | COMPLETED | Drug: montelukast Drug: placebo |
Bronchial Hyperreactivity Cough |
Isala | 2007-12 | Phase 4 |
| NCT02029313 | COMPLETED | Drug: Montelukast Drug: Montelukast sodium |
Asthma and Allergic Rhinitis | PharmaKing | 2013-11 | Phase 1 |
| NCT02793375 | ACTIVE, NOT RECRUITING | Drug: Montelukast Drug: Placebo |
Pain | Children's Hospital Medical Center, Cincinnati | 2018-08-02 | Phase 3 |
| NCT00565955 | COMPLETED | Drug: montelukast Drug: Placebo |
Bronchial Asthma | All India Institute of Medical Sciences, New Delhi | 2007-03 | Phase 3 |
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
